Introduction {#s1}
============

Extensive drug-resistant (XDR) *Pseudomonas aeruginosa* is a major burden to the global health-care system and has been highlighted by the World Health Organization as a priority pathogen with "Serious" threat to human health ([@B35]; [@B15]; [@B52]). Due to the dry discovery pipeline, few novel classes of antibiotics will become available in the near future ([@B4]). "Old" polymyxins (i.e., polymyxin B and colistin, also known as polymyxin E) are a last-line therapy that are increasingly used for life-threatening infections caused by XDR *P. aeruginosa* ([@B13]; [@B30]; [@B38]; [@B54]; [@B40]; [@B6]). Although polymyxins remain effective against XDR *P. aeruginosa*, recent pharmacokinetic/pharmacodynamic (PK/PD) studies suggest that polymyxin monotherapy is potentially associated with increased emergence of resistance ([@B48]; [@B7]; [@B8]). Moreover, reports of infections caused by XDR *P. aeruginosa*, including polymyxin-resistant XDR isolates, are on the rise ([@B22]; [@B2]; [@B14]; [@B18]). In a recent *in vitro* PK/PD study, we demonstrated that polymyxin B in combination with enrofloxacin is highly effective against XDR *P. aeruginosa*, which is resistant to both, and significantly minimizes the emergence of polymyxin resistance ([@B31]). However, the underlying mechanism of the synergistic killing by this novel drug combination remains unknown.

Metabolomics investigates dynamic global metabolite levels in biological systems in response to biological stimuli or perturbations ([@B9]; [@B24]; [@B34]; [@B51]). To date, metabolomics is increasingly employed in drug discovery and development to elucidate the mechanism of drug action ([@B41]). In the present study, we investigated the synergistic killing mechanism of polymyxin B and enrofloxacin combination against a clinical isolate of XDR *P. aeruginosa* using metabolomics. The mechanistic findings provide important pharmacological information for optimizing this promising combination in patients.

Materials and Methods {#s2}
=====================

Chemicals and Reagents {#s2_1}
----------------------

A solution of polymyxin B (sulfate, Sigma-Aldrich, Castle Hill, NSW, Australia; batch number BCBD1065V) was freshly prepared in sterile Milli-Q water (Millipore Australia, North Ryde, NSW, Australia). Enrofloxacin (Sigma-Aldrich) was first dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and subsequently diluted in sterile Milli-Q water to obtain a final DMSO concentration of ≤10% (v/v) ([@B49]).

Bacterial Strain and Culture {#s2_2}
----------------------------

An XDR *P. aeruginosa* 12196 with a polymyxin MIC of 64 mg/L and enrofloxacin MIC of 4 mg/L was examined ([@B31]). *P. aeruginosa* 12196 was stored in tryptone soy broth with 20% glycerol at −80°C and sub-cultured onto nutrient agar plates before each experiment ([@B32]; [@B33]). Overnight culture was subsequently prepared in 10-ml cation-adjusted Mueller-Hinton broth (CAMHB) and diluted 100-fold using fresh media to prepare 200 ml of mid-logarithmic culture with a starting inoculum of approximately 10^8^ CFU/ml ([@B32]; [@B33]). To each bacterial culture, polymyxin B (2 mg/L), enrofloxacin (1 mg/L), or a combination was added. Bacterial culture without any antibiotics served as a control. Three biological replicates were prepared independently from different colonies of XDR *P. aeruginosa* 12196 on three consecutive days. Bacterial cultures were incubated at 37°C in a shaking incubator (180 rpm). Samples were collected at 0, 1, and 4 h and immediately quenched in a dry ice--ethanol bath for 30 s to halt the metabolism. Subsequently, the OD~600~ value of each sample was measured and normalized to 0.50 ± 0.02 with fresh CAMHB. Subsequently, 15 ml of each normalized sample culture was transferred to 15-ml Falcon tubes (Thermo Fisher Scientific, Melbourne, Australia) for metabolite extraction.

Sample Preparation for Metabolomics Experiments {#s2_3}
-----------------------------------------------

Metabolite sample preparation was carried out as reported previously ([@B19]). Briefly, 15 ml of each bacterial culture was centrifuged at 3,200 × *g* at 4 C. The supernatant was discarded, and cell pellets were resuspended in cold 0.9% sodium chloride solution. Samples were centrifuged at 3,200 × *g* for 5 min to remove extracellular metabolites and media components. Following the washing step, bacterial pellets were resuspended in 0.5 ml of chloroform/methanol/water (1:3:1, v/v/v) containing 1 µM internal standards (CHAPS, CAPS, PIPES, and TRIS). Subsequently, bacterial samples were frozen in liquid nitrogen and thawed on ice to release intracellular metabolites. The samples were then centrifuged at 14,000 × *g* for 10 min, and 200 µL of supernatants was transferred into ultra-performance liquid chromatography (UPLC) vials for liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis. QC samples were prepared by mixing equal amounts of all tested samples and processed as a "real" sample outlined above.

LC-MS/MS Analysis for Metabolomics {#s2_4}
----------------------------------

Metabolite samples were analyzed on a Q-exactive Orbitrap mass spectrometer coupled with a Dionex U3000 high-performance LC (HPLC; Thermo Fisher) with a ZIC-pHILIC column (5 µm, polymeric, 150 × 4.6 mm; SeQuant, Merck). The MS system was operated at 35,000 resolution in both positive and negative electrospray ionization modes with a detection range of 85--1,275 *m*/*z*. Column temperature was maintained at 25 C, and the mobile phase consisted of 20 mM of ammonium carbonate (solvent A) and acetonitrile (solvent B). Metabolites were eluted in a step gradient, starting with 80% solvent B at a flow rate of 0.3 ml/min followed by a linear gradient to 50% solvent B over 15 min ([@B32]; [@B33]). All samples were randomized and analyzed in a single LC-MS batch. Analytical reproducibility was monitored on the basis of pooled QC samples throughout the batch, which were periodically analyzed after groups of six samples. Analyses of a mixture of pure standards containing \>250 metabolites were performed to assist in the identification of metabolites.

Bioinformatics and Pathway Analyses {#s2_5}
-----------------------------------

IDEOM (<http://mzmatch.sourceforge.net/ideom.php>) and mzMatch were employed for metabolomics analysis ([@B46]; [@B11]). Raw mass spectrometric data files were processed as described previously based on the intensity (\>100,000 counts), shape (codadw \> 0.8), and reproducibility (RSD \< 0.5) of the LC-MS peaks. Elemental composition and exact mass were used for open-source database searching, including MassBank (<http://www.massbank.jp>). Putative metabolites were identified by accurate mass (±5 ppm) and retention time with authentic standards (\<50%) as indicated by IDEOM confidence score of 9 or 10, or by accurate mass (±5 ppm) and predicted retention time to achieve an IDEOM confidence scores of ≥5 ([@B11]). Several different databases \[e.g., *PseudoCyc*, Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCyc HMDB, and LipidMaps\] were used to map the metabolite, and global metabolomics profiles of samples were analyzed using univariate and multivariate analyses in MetaboAnalyst 4.0 ([@B53]). Data were filtered using interquartile range (IQR), normalized relative to the median, log~2~ transformed, and auto-scaled. PCA was performed to identify and remove outliers that were defined as samples outside of ±2 standard deviations (SDs) along the principal component 1 axis (PC1). Statistical significance of differences between metabolites was determined using one-way analysis of variance (ANOVA), Benjamini--Hochberg multiple testing correction (*q* \< 0.05), Fisher's least significant difference (LSD) test, and fold change (FC; log~2~FC ≥ 1). FC values were calculated using raw intensity and geometric mean of the biological replicates. BioCyc ([@B26]), iPath ([@B29]), and the KEGG ([@B25]) were employed for pathway analysis.

Results {#s3}
=======

Metabolomics Profiles of *Pseudomonas aeruginosa* Treated With Polymyxin B, Enrofloxacin, and the Combination {#s3_1}
-------------------------------------------------------------------------------------------------------------

The intra-experimental variability was assessed based on the median relative standard deviations (RSDs) of the samples, which ranged from 15% to 24% ([**Figure S1**](#SM2){ref-type="supplementary-material"}) and were well within the acceptable limits for metabolomics studies ([@B27]). Furthermore, the principal component analysis (PCA) plots showed that all samples \[including six quality control (QC) samples\] were tightly clustered together, demonstrating an excellent reproducibility of our analytical methods ([**Figure S1**](#SM2){ref-type="supplementary-material"}). Univariate and multivariate analyses revealed that over 500 putative metabolites were identified in the metabolome of XDR *P. aeruginosa* 12196 induced by polymyxin B (2 mg/L) and enrofloxacin (1 mg/L) alone or in combination at 1- and 4-h postdrug treatment. The nature of these metabolites indicated that a wide range of pathways were perturbed ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}; [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}). Univariate analysis showed that polymyxin B alone induced 6.3% (36) and 5.3% (30) metabolic changes at 1 and 4 h, respectively. Likewise, the combination induced 11.4% (65) and 21.8% (124) metabolic changes at 1 and 4 h, respectively. On the other hand, enrofloxacin alone induced minimal metabolic changes at 1 h ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}). PCA demonstrated that polymyxin B alone and in combination with enrofloxacin induced significant global metabolic changes as early as 1 h ([**Figure 1A**](#f1){ref-type="fig"}). Perturbations in the metabolome of XDR P. aeruginosa 12196 induced by polymyxin B (2 mg/L) and enrofloxacin (1 mg/L) alone or in combination were evident at 1 and 4 h post drug treatment. Many metabolic features were shared between the two monotherapies and the combination with more significant changes at 4 h, demonstrating a time-dependent antibacterial effect by the drug combination ([**Figure 1B**](#f1){ref-type="fig"}). At 1 h, the number of perturbed metabolites that were common between polymyxin B alone and the combination was much higher than that between enrofloxacin alone and the combination. Interestingly, at 4 h, the metabolic alterations were largely caused by the combination ([**Figure 1B**](#f1){ref-type="fig"}). Overall, the combination of polymyxin B and enrofloxacin produced significantly greater perturbations in the metabolomes at 1 and 4 h than either polymyxin B or enrofloxacin alone.

![Metabolomics analyses of XDR *P. aeruginosa* 12196 treated with polymyxin B (PMB) and enrofloxacin (ENRO) alone or in combination (PMB/ENRO). **(A)** Principal component analysis (PCA) score plots for the metabolites from bacterial cultures treated with polymyxin B, enrofloxacin, and the combination at 1 and 4 h. Green, light blue, purple, and red represent untreated control, polymyxin B alone (PMB), enrofloxacin alone (ENRO), and the combination (COMB), respectively. **(B)** Venn diagram for the comparison of the numbers of metabolites that were significantly altered by each treatment at each time point. Significant metabolites were selected based on log~2~ fold change (FC) ≥ 1 and *q* \< 0.05. **(C)** Bipartite graph connected different treatment groups with significantly altered metabolites in major classes.](fphar-10-01146-g001){#f1}

![Heatmap profiles of the relative abundance of putative metabolites in XDR *P. aeruginosa* 12196 following treatment with polymyxin B alone (PMB), enrofloxacin alone (ENRO), and its combination (PMB + ENRO) at 1 and 4 h. Metabolites were grouped into different classes: amino acids, carbohydrates, energy, lipids (lipid metabolism, fatty acids, and phospholipids), co-factors and vitamins, nucleotides, and peptides. Only the significantly perturbed metabolites in the major perturbed pathways are included. Data represent log~2~FC compared with the untreated control samples at respective time points.](fphar-10-01146-g002){#f2}

Pathway analyses revealed that multiple metabolic pathways were affected by antibiotic treatments. In details, at 1 and 4 h polymyxin B alone significantly perturbed phospholipid and fatty acid metabolisms, whereas enrofloxacin alone had minimal metabolic perturbations on both metabolic pathways ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f1){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}). On the contrary, the combination therapy significantly perturbed a greater number of key metabolic pathways, including lipid, carbohydrate, nucleotide, and energy metabolism ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f1){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}). The levels of perturbed metabolites are provided in [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}.

Perturbations in Phospholipid and Fatty Acid Levels, and Lipid A Modification Pathway {#s3_2}
-------------------------------------------------------------------------------------

Polymyxin B alone and its combination with enrofloxacin significantly perturbed phospholipid and fatty acid levels at 1- and 4-h posttreatment ([**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"}). More specifically, at 4 h, the drug combination significantly decreased the levels of phospholipids, phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylglycerol (PG) ([**Figure 3**](#f3){ref-type="fig"}). Enrofloxacin alone did not have a significant impact on phospholipid levels. Interestingly, the decreased phospholipid levels were accompanied with an accumulation of a large number of fatty acids intracellularly at 4 h ([**Figure 3**](#f3){ref-type="fig"}). Importantly, at 4 h, polymyxin B alone led to significantly increased levels of uridine 5′-diphospho-beta-(4-deoxy-4-formamido-l-arabinose) (UDP-l-Ara4FN) (log~2~FC = 2.95), a key precursor of 4-amino-4-deoxy-l-arabinose (l-Ara4N)-modified lipid A but not in the groups of enrofloxacin alone (log~2~FC = 0.11) or the combination (log~2~FC = 0.79) ([**Figure 2**](#f2){ref-type="fig"}).

![Metabolic perturbations in the phospholipid and fatty acid pathway following treatments with polymyxin B, enrofloxacin, and the combination against XDR *P. aeruginosa* 12196. Data represent log~2~FC compared with the untreated control samples at respective time points.](fphar-10-01146-g003){#f3}

Polymyxin B and Enrofloxacin Combination Significantly Altered Nucleotide Metabolism and Decreased Energy Metabolism {#s3_3}
--------------------------------------------------------------------------------------------------------------------

Several intermediate metabolites in pyrimidine metabolism were significantly enriched at 4 h by the combination. In particular, the levels of deoxycytidine (log~2~FC = 2.04), deoxycytidine monophosphate (dCMP; log~2~FC = 1.10), deoxycytidine diphosphate (dCDP; log~2~FC = 1.78), thymine (log~2~FC = 1.95), thymidine (log~2~FC = 1.43), deoxythymidine monophosphate (dTMP; log~2~FC = 1.82), and uridine diphosphate (UDP; log~2~FC = 1.27) were all significantly increased at 4 h by the combination ([**Figure 4**](#f4){ref-type="fig"}). For each monotherapy, only UDP (log~2~FC = 2.48) was elevated following polymyxin B alone at 4 h, while levels of deoxycytidine (log~2~FC = 1.06), thymine (log~2~FC = 1.24), and thymidine (log~2~FC = 1.02) were significantly increased by enrofloxacin alone at 4 h ([**Figure 4**](#f4){ref-type="fig"}).

![Metabolic perturbations in nucleotide metabolism at 1 and 4 h. Data represent log~2~FC relative to untreated control samples at respective time points.](fphar-10-01146-g004){#f4}

In contrast, the combination significantly decreased the levels of the metabolites in purine metabolism at 1 or 4 h. In details, the levels of guanosine monophosphate (GMP; log~2~FC = −2.02) and guanosine diphosphate (GDP; log~2~FC = −1.32) were significantly decreased by the combination at 1 h, whereas at 4 h, adenosine monophosphate (AMP; log~2~FC = −1.37) was significantly decreased ([**Figure 4**](#f4){ref-type="fig"}). Polymyxin B alone also significantly perturbed GMP (log~2~FC = −2.62) at 1 h but had a minimal effect on purine nucleotide metabolism at 4 h ([**Figures 4**](#f4){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}; [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}). At the examined concentration, enrofloxacin alone had a minimal effect on purine metabolism at 1 and 4 h.

In addition to nucleotide metabolism, metabolites related to energy metabolism were significantly depleted by the combination but not the monotherapies (except for sedoheptulose 1-phosphate). Specifically, at 1 and 4 h, two important redox co-factors, flavin mononucleotide (FMN; log~2~FC = −0.31 and −1.37, respectively) and nicotinamide adenine dinucleotide phosphate (NADPH; log~2~FC = −1.63 and −5.57, respectively), were significantly depleted by the combination ([**Figure 5**](#f5){ref-type="fig"} and [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}). Neither polymyxin B nor enrofloxacin alone exhibited significant effects on the levels of redox co-factors at 1 and 4 h.

![Depletion of key redox co-factors following treatments with polymyxin B, enrofloxacin, and the combination against XDR *P. aeruginosa* 12196. Bars labeled with an asterisk indicate significant changes in the abundance of metabolites (*q* \< 0.05; ≥1 − log~2~FC). Data represent means of normalized intensity ± standard deviation (*n* = 3). Intensity was normalized relative to the median, log~2~ transformed, and auto-scaled.](fphar-10-01146-g005){#f5}

Polymyxin B and Enrofloxacin Combination Perturbed the Pentose Phosphate Pathway and Cell Envelop Biogenesis {#s3_4}
------------------------------------------------------------------------------------------------------------

The combination of polymyxin B and enrofloxacin significantly perturbed key intermediates in the pentose phosphate pathway (PPP) ([**Figure 6**](#f6){ref-type="fig"}). Two key intermediate metabolites, d-ribose 5-phosphate (log~2~FC = −1.02 and −0.72, respectively) and d-sedoheptulose 7-phosphate (log~2~FC = −1.29 and −1.52, respectively), were significantly decreased at 1 h by polymyxin B alone and the combination. Interestingly, d-ribose 5-phosphate (log~2~FC = 1.47) and d-sedoheptulose 7-phosphate (log~2~FC = 1.75) were significantly enriched by the combination at 4 h (log~2~FC ≥ 1, *q* \< 0.05) ([**Figure 6**](#f6){ref-type="fig"}). Notably, neither glycolysis nor citric acid cycle was significantly perturbed by each monotherapy or the combination at the tested concentrations ([**Figure S2**](#SM2){ref-type="supplementary-material"} and [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}).

![Metabolic perturbations in the pentose phosphate pathway in XDR *P. aeruginosa* 12196. Orange boxes indicate the metabolites that were significantly perturbed. Bar charts show the raw intensity at respective time points (1 and 4 h), and bars labelled with an asterisk indicate significant changes in the abundance of metabolites (*q* \< 0.05; ≥1 − log~2~FC). Raw intensity was normalized relative to the median, log~2~ transformed, and auto-scaled. Data represent geometric means of normalized intensity ± standard deviation (*n* = 3).](fphar-10-01146-g006){#f6}

Cell envelope biogenesis was significantly perturbed following treatments with the polymyxin B--enrofloxacin combination ([**Figure 7**](#f7){ref-type="fig"}). The level of UDP-*N*-acetyl-d-glucosamine (log~2~FC = −2.07) was decreased at 1 h in response to polymyxin B alone but increased at 4 h following treatment with the combination (log~2~FC = 2.45). Interestingly, a similar trend was also observed for UDP-*N*-acetylmuramoyl-l-alanyl-d-glutamyl-6-carboxyl-lysyl-d-alanyl-d-alanine at 4 h in response to the combination (log~2~FC = 1.45), whereas enrofloxacin alone had minimal effects on the cell envelope biogenesis pathway at either time point ([**Figure 7**](#f7){ref-type="fig"}).

![Metabolic perturbations in cell envelope biogenesis in XDR *P. aeruginosa* 12196. Orange boxes indicate the metabolites that were significantly increased. Bar charts show raw intensity at respective time points (1 and 4 h). Bars labelled with an asterisk indicate significant changes in the abundance of metabolites (q \< 0.05; ≥1 − log~2~FC). Raw intensity was normalized relative to the median, log~2~ transformed, and auto-scaled. Data represent geometric means of normalized intensity ± standard deviation (*n* = 3).](fphar-10-01146-g007){#f7}

Discussion {#s4}
==========

Resistance to the last-resort polymyxins can emerge after monotherapy ([@B3]; [@B1]; [@B47]; [@B50]); therefore, rational polymyxin combinations with other antibiotics have been strongly recommended from the PK/PD perspective ([@B39]). The use of polymyxin B in combination with enrofloxacin, a fluoroquinolone, is highly effective against polymyxin- and enrofloxacin-resistant XDR *Pseudomonas aeruginosa* ([@B31]). To our knowledge, the present study is the first to demonstrate that the synergistic killing of polymyxin B in combination with enrofloxacin was time dependent, which was initially facilitated by polymyxin B and subsequently driven by enrofloxacin.

Enrofloxacin is partially metabolized into ciprofloxacin *in vivo* by the cytochrome P450 enzymes ([@B28]; [@B23]; [@B17]; [@B36]; [@B43]), and its PK profile in humans is currently undetermined; therefore, clinically achievable concentrations of ciprofloxacin were used for enrofloxacin (1 mg/L) in the present study ([@B44]). Polymyxin B was examined at 2 mg/L to ensure the clinical relevance of our findings ([@B45]). With an inoculum of 10^8^ CFU/ml, neither 2 mg/L of polymyxin B nor 1 mg/L of enrofloxacin had a significant killing effect on XDR *P. aeruginosa* 12196; surprisingly, the combination of polymyxin B and enrofloxacin exhibited synergistic killing at 4 h. In order to understand the molecular basis of the dynamic extensive killing, bacterial metabolic profiles were examined at 1 and 4 h following antibiotic treatment ([**Figure 1**](#f1){ref-type="fig"}).

Consistent with the phenotypical synergistic killing observed in our previous PK/PD studies, our metabolomics results showed that the combination was clearly separated from each monotherapy alone at both time points ([**Figure 1**](#f1){ref-type="fig"}). Metabolic pathway analyses revealed that the synergistic killing of polymyxin B--enrofloxacin combination was attributed to the perturbations of key metabolic pathways, including lipid, carbohydrate, nucleotide, and energy metabolism ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}; [**Supplementary Tables 1--2**](#SM1){ref-type="supplementary-material"}). A large number of metabolites associated with fatty acids and lipids were significantly perturbed following polymyxin B alone and the combination at 1 and 4 h ([**Figure 3**](#f3){ref-type="fig"}). These findings are in agreement with the primary mode of action of polymyxins *via* the disruption of the bacterial outer membrane ([@B30]). Notably, this finding is also consistent with previous results in *Acinetobacter baumannii*, in which colistin significantly perturbed the gene expression and metabolites in fatty acid and lipid metabolism ([@B20]; [@B33]). On the contrary, enrofloxacin alone did not affect fatty acid and lipid metabolisms at 1 and 4 h ([**Figures 1**](#f1){ref-type="fig"}, [**3**](#f3){ref-type="fig"} and [**S2**](#SM2){ref-type="supplementary-material"}), which is consistent with its mode of action by the inhibition of topoisomerase II (DNA gyrase) and prevention of the replication of DNA ([@B28]; [@B23]; [@B17]; [@B36]; [@B43]). DNA damage activates the SOS gene network that results in the production of DNA repair proteins ([@B42]) and the accumulation of nucleotides ([@B12]). Furthermore, transcriptomic analysis of *Staphylococcus aureus* showed that fluoroquinolone treatment up-regulates the expression of ribonucleotide reductases and several genes involved in the DNA repair pathways ([@B10]). This finding is consistent with the metabolomics data obtained in the present study with *P. aeruginosa*. Our results showed that SOS responses induced by enrofloxacin alone and the combination resulted in the accumulation of pyrimidine metabolites to cope with the inhibition of DNA replication at 4 h ([**Figure 4**](#f4){ref-type="fig"}). Consistently, the level of d-ribose 5-phosphate in PPP, a key precursor in nucleotide metabolism, was also significantly increased following the treatment with the combination at 4 h, but not at 1 h when polymyxin killing predominated ([**Figure 6**](#f6){ref-type="fig"}). Overall, our metabolomics results highlight the dominant effect of enrofloxacin on the synergy observed with the combination at 4 h.

Despite the largely overlapping metabolic perturbations between polymyxin B or enrofloxacin alone and the combination, the present data revealed that the synergistic combination induced several unique metabolic alterations in energy metabolism ([**Figures 2**](#f2){ref-type="fig"} and [**5**](#f5){ref-type="fig"}) and cell envelope biogenesis ([**Figure 7**](#f7){ref-type="fig"}). It is evident that the combination uniquely caused a significant depletion of key redox co-factors, including FMN and NADPH, at 1- and 4-h posttreatment ([**Figure 5**](#f5){ref-type="fig"}). It is likely that *P. aeruginosa* diverted the energy required to synthesize nucleotides toward DNA repair, as a result of the activation of the SOS gene network. The observed decrease in energy metabolism coupled with significant perturbations in PPP suggests an imbalanced redox state due to the treatment with this combination. Interestingly, at 4 h, the combination led to significant increase in fatty acids levels and decrease in phospholipid levels ([**Figure 3**](#f3){ref-type="fig"}). These alterations might be attributed to the reduced utilization as an energy source and membrane remodelling. Overall, our findings indicate that the inhibition of energy metabolism plays a key role in the mechanism of synergistic bacterial killing by the combination at 4 h.

Moreover, the combination displayed significant and persistent effects on the cell envelope biogenesis in XDR *P. aeruginosa* ([**Figure 7**](#f7){ref-type="fig"}). At 4 h, a significant increase in the levels of a peptidoglycan biosynthesis metabolite UDP-*N*-acetylmuramoyl-l-alanyl-d-glutamyl-6-carboxy-l-lysyl-d-alanyl-d-alanine was observed with the combination ([**Figure 7**](#f7){ref-type="fig"}). In *Streptococcus faecalis*, the inhibition of DNA replication by a fluoroquinolone resulted in the formation of thicker cell wall ([@B21]). It is very likely that the synergistic killing at 4 h by the combination is driven by the secondary antibiotic, enrofloxacin. In addition to the inhibition of cell wall biogenesis, the combination synergistically inhibited the lipopolysaccharide (LPS) modification pathway ([**Figure 2**](#f2){ref-type="fig"}). Polymyxin B alone against *P. aeruginosa* leads to the development of resistance most commonly *via* lipid A modification with aminoarabinose ([@B37]). UDP-l-Ara4FN, a key precursor of lipid A modification ([@B5]; [@B16]), was significantly enriched following the treatment with polymyxin B alone at both 1 and 4 h; however, this effect was not observed with the combination ([**Figure 2**](#f2){ref-type="fig"}). Our results clearly demonstrated that polymyxin resistance *via* the lipid A modification can emerge rapidly (e.g., as early as in 1 h) even in resistant isolates. Importantly, the inhibition of polymyxin resistance by enrofloxacin plays a key role in the synergistic antibacterial killing. From a PK/PD perspective, our metabolomics results are clinically significant and highlight the importance of a combination therapy in minimizing the development of resistance to the last-line polymyxins.

Conclusions {#s5}
===========

The development of effective polymyxin combination therapy is of utmost importance in response to the increasing incidence of infections caused by XDR Gram-negative "superbugs." To the best of our knowledge, this is the first systems pharmacology study to investigate the synergistic effect of polymyxins with a fluoroquinolone antibiotic against XDR *P. aeruginosa*, which is resistant to all antibiotics, including polymyxins and fluoroquinolones. Importantly, co-administration of enrofloxacin reduced the emergence of polymyxin resistance by inhibiting lipid A modification. These results provide important mechanistic insights into optimizing the clinical use of this promising combination using PK/PD approaches.
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